Sandra Sharpe-Cohen

Learn More
To evaluate the role of V3-specific IgG antibodies (Abs) in the RV144 clinical HIV vaccine trial, which reduced HIV-1 infection by 31.2%, the anti-V3 Ab response was assessed. Vaccinees' V3 Abs were highly cross-reactive with cyclic V3 peptides (cV3s) from diverse virus subtypes. Sieve analysis of CRF01_AE breakthrough viruses from 43 vaccine- and 66(More)
Experiments were performed to determine if focusing the immune response on a single neutralizing epitope of gp120 would result in cross-clade neutralizing antibodies (Nabs). Thus, rabbits were immunized with 2–3 priming doses of gp120 DNA (from clades A, B, or C) and with two boosters of fusion proteins carrying the consensus V3 epitope from either clades(More)
  • 1